Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms
- PMID: 16490286
- DOI: 10.1016/j.neuint.2005.12.005
Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms
Abstract
Clusterin is suggested to be involved in the pathogenesis of Alzheimer's disease. Clusterin expression is increased in brain tissue in affected regions of Alzheimer patients, and intense clusterin staining is found in both senile plaques and in neuronal and glia cells. In contrast, the cerebrospinal fluid level of clusterin in Alzheimer patients has, thus far, been found unchanged. Clusterin is a glycosylated protein, and an alteration of its glycosylation in Alzheimer's disease might influence accurate quantification in cerebrospinal fluid through interference of antibody binding to the protein. Using enzymatic deglycosylation of clusterin isolated from cerebrospinal fluid, we found that the carbohydrates attached to clusterin were of the N-linked type and sialic acids. Based on this finding, cerebrospinal fluid samples from Alzheimer patients (n=99) and controls (n=39) were analysed. The samples were treated with peptide: N-glycanase F, cleaving off N-linked carbohydrates, and clusterin was quantified before and after deglycosylation using a new sandwich enzyme-linked immunosorbent assay. Clusterin was significantly increased in Alzheimer patients, in both native (7.17+/-2.43 AU versus 5.73+/-2.09 AU; p=0.002), and deglycosylated samples (12.19+/-5.00 AU versus 9.68+/-4.38 AU; p=0.004). Deglycosylation led to increased measured levels of clusterin by 70% (p<0.001) in Alzheimer patients and 67% (p<0.001) in controls. These findings indicate that glycosylation of proteins may interfere with their quantification. The results show that clusterin is significantly increased in cerebrospinal fluid from Alzheimer patients as a group, supporting that clusterin might be involved in the pathogenesis of Alzheimer's disease. However, the individual clusterin levels overlap between the two groups, and thus cerebrospinal fluid clusterin measurement is not suitable as a biochemical marker in the diagnosis of Alzheimer's disease.
Similar articles
-
Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss?Neurosci Lett. 2009 Feb 6;450(3):332-5. doi: 10.1016/j.neulet.2008.11.015. Epub 2008 Nov 12. Neurosci Lett. 2009. PMID: 19022350
-
Subgroups of Alzheimer's disease based on cerebrospinal fluid molecular markers.Ann Neurol. 2005 Nov;58(5):748-57. doi: 10.1002/ana.20639. Ann Neurol. 2005. PMID: 16247771
-
Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596. Arch Neurol. 2009. PMID: 19273758
-
Novel ventriculo-peritoneal shunt in Alzheimer's disease cerebrospinal fluid biomarkers.Expert Rev Neurother. 2004 Jan;4(1):97-107. doi: 10.1586/14737175.4.1.97. Expert Rev Neurother. 2004. PMID: 15853620 Review.
-
Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging?Neurobiol Aging. 2007 Oct;28(10):1465-80. doi: 10.1016/j.neurobiolaging.2006.06.021. Epub 2006 Jul 31. Neurobiol Aging. 2007. PMID: 16876913 Review.
Cited by
-
Transthyretin Amyloidosis: Chaperone Concentration Changes and Increased Proteolysis in the Pathway to Disease.PLoS One. 2015 Jul 6;10(7):e0125392. doi: 10.1371/journal.pone.0125392. eCollection 2015. PLoS One. 2015. PMID: 26147092 Free PMC article.
-
Clusterin in Alzheimer's Disease: Mechanisms, Genetics, and Lessons From Other Pathologies.Front Neurosci. 2019 Feb 28;13:164. doi: 10.3389/fnins.2019.00164. eCollection 2019. Front Neurosci. 2019. PMID: 30872998 Free PMC article. Review.
-
Association between CLU gene rs11136000 polymorphism and Alzheimer's disease: an updated meta-analysis.Neurol Sci. 2018 Apr;39(4):679-689. doi: 10.1007/s10072-018-3259-8. Epub 2018 Feb 2. Neurol Sci. 2018. PMID: 29396813
-
Mass spectrometry quantification of clusterin in the human brain.Mol Neurodegener. 2012 Aug 20;7:41. doi: 10.1186/1750-1326-7-41. Mol Neurodegener. 2012. PMID: 22906254 Free PMC article.
-
Advances in Genetic and Molecular Understanding of Alzheimer's Disease.Genes (Basel). 2021 Aug 15;12(8):1247. doi: 10.3390/genes12081247. Genes (Basel). 2021. PMID: 34440421 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous